Trials / Completed
CompletedNCT05161208
OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers
Randomized, Controlled, Double-masked Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline) Nasal Spray on Objective and Subjective Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Center for Ophthalmic and Vision Research, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study is a single center, prospective, randomized, controlled, double-masked, two-arm investigator-initiated study to investigate the efficacy of OC-01 (varenicline) nasal spray on the signs and symptoms of dry eye disease in daily soft contact lens wearers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OC-01 (varenicline 0.6mg/ml) Nasal Spray | Intranasal delivery of OC-01 nasal spray twice daily (BID) |
| DRUG | Placebo (vehicle) nasal spray | Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID) |
Timeline
- Start date
- 2021-12-03
- Primary completion
- 2022-07-25
- Completion
- 2022-07-25
- First posted
- 2021-12-17
- Last updated
- 2022-11-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05161208. Inclusion in this directory is not an endorsement.